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PICTURE QUIZ
Awomanwith raised alkaline phosphatase and forearm
deformity
Joanne K Y Lam resident , Karen S L Lam professor , Annie W C Kung professor , Kathryn C B
Tan professor , Wing-Sun Chow associate consultant , Annette W K Tso assistant professor
Queen Mary Hospital, Pokfulam Road, Hong Kong
A 71 year old Chinese woman was referred from the general
outpatient clinic to our endocrine clinic for evaluation of raised
serum alkaline phosphatase (ALP), which had been measured
as part of a routine check-up. Apart from a history of
hypertension and gout, she was well. For the past two years her
blood tests had shown a raised ALP (183-277 U/L; reference
range 47-124). Liver enzymes, renal function tests, thyroid
function tests, and adjusted calcium and phosphate
concentrations were all within normal ranges.
Examinations of the abdomen, cardiovascular system, and
respiratory system were normal. She was noted to have a
deformity of the right forearm (fig 1). She denied a history of
trauma or fracture. The deformity had been present for three
years, but she had not sought medical advice because it did not
affect her hand function and was not painful. A radiograph of
the right forearm was taken (fig 2).
Fig 1 Deformity of the right forearm
Fig 2 Radiograph of the right forearm
Questions
1 What is the diagnosis?
2 Describe the radiological abnormalities that confirm the
diagnosis
3 How would you treat this condition?
Answers
1 What is the diagnosis?
Short answer
The diagnosis is Paget’s disease of bone.
Long answer
Paget’s disease of bone was first described by James Paget, who
named this skeletal condition “osteitis deformans” in 1877.1 It
is a disease of bone remodelling and is characterised by
excessive bone resorption at affected skeletal sites, followed by
disorganised bone formation. The overproduced bone is sclerotic
and of poor quality, and it is susceptible to deformity and
fracture.2 Paget’s disease of bone is the second most common
metabolic bone disease in European countries. The prevalence
of Paget’s disease in the United Kingdom has been estimated
at 5% in people over 55 years of age.3 Paget’s disease, however,
is rare in Chinese people. The prevalence of Paget’s disease in
non-white populations is not known because few case reports
and case series are found in the literature.4 5 Pagetic lesions are
usually found in the pelvis, spine, skull, and long bones of the
lower extremities. Paget’s disease of the radius is rarely
reported.6Most patients with Paget’s disease are asymptomatic.
Around 5% of patients have symptoms including bone pain,
bowing of long bones, skull deformities, fractures, and nerve
entrapment syndromes.7
The diagnosis is usually made using plain radiographs (see
below). Plain radiographs are also useful in the diagnosis of
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secondary complications such as contiguous arthritis and
fractures. Radionuclide bone scan using a radiolabelled
bisphosphonate is highly sensitive in assessing the extent of
skeletal involvement.8 However, it is not specific to Paget’s
disease—focal uptake or “hot spots” can also be seen in
fractures, infections, and evenmetastases. Any increased uptake
in bone scan should be followed by targeted radiographs.
Serum alkaline phosphatase is a sensitive marker of bone
formation, and concentrations are increased in 85% of patients
with Paget’s disease of bone.9 In patients with monostotic
disease (only one bone affected; about 15% of cases) or
underlying liver derangement, bone specific alkaline
phosphatase may be more useful.10 Bone formation markers,
such as procollagen type 1 N-terminal propeptide (P1NP), and
bone resorption markers, such as urinary pyridinoline, are
usually raised, but they are not widely available and are seldom
used for diagnosis or monitoring of disease activity.11
Bone biopsy is rarely needed for the diagnosis, but it might help
exclude osteosarcoma or bone metastases. Histological analysis
typically shows an increase in bone resorption, with large
multinucleated osteoclasts and increased bone marrow fibrosis
surrounding bone trabeculae.
2 Describe the radiological abnormalities that
confirm the diagnosis
Short answer
This radiograph shows cortical thickening of the radius and
ulnar with a coarse trabecular pattern and bowing of the radius.
Sclerosis of the distal radius is also seen, as well as lytic lesions
in the shaft of the radius (fig 3).
Fig 3 Radiograph of the right forearm showing sclerosis
of the distal radius and lytic lesions in the shaft of the radius
Long answer
Paget’s disease is usually diagnosed with the use of plain
radiographs. The characteristic radiological findings are most
prominent in the skull and long bones. Initially, osteolysis of
the skull causes “osteoporosis circumscripta,” which is seen as
radiolucent areas on radiographs. This is followed by excessive
formation of new bone, which leads to cortical thickening,
“cotton wool” appearance as a result of localised sclerosis, and
skull enlargement. The long bones typically show cortical
thickening and enlargement, mixed areas of sclerotic and lytic
lesions, and bowing deformities. If the vertebral body is affected
a characteristic “picture frame” appearance is seen, as a result
of enlargement of the vertebral body.10
3 How would you treat this condition?
Short answer
Bisphosphonates are the gold standard treatment. The aim is to
decrease the abnormal bone turnover caused by osteoclastic
bone resorption.
Long answer
Treatment is not warranted in asymptomatic patients who have
normal serum alkaline phosphatase or a normal bone scan.
Indications for treatment include symptoms that are caused by
metabolically active Paget’s disease, such as bone pain, joint
pain, headache (when the skull is affected), or neurological
symptoms; planned surgery at a metabolically active pagetic
site (treatment can decrease intraoperative bleeding); the
presence of immobilisation hypercalcaemia; serum alkaline
phosphatase concentration more than 1.5 times the upper limit
of normal; and prevention of disease progression or future
complications.12
Around 5% of patients with Paget’s disease of bone experience
bone pain.7 They may benefit from simple analgesics, low dose
tricyclic antidepressants, and physical methods, including
transcutaneous electric nerve stimulation.13 Surgery may be
warranted if pain is caused by osteoarthritis or nerve
compression.13
Bisphosphonates are the mainstay of medical treatment in
Paget’s disease of bone, which aims to suppress the abnormal
bone turnover.13 Five bisphosphonates are currently indicated
for the treatment of Paget’s disease of bone:
• Zoledronic acid (5 mg infusion)14 15
• Pamidronate (30 mg or 60 mg infusion every three
months)16
• Risedronate (30 mg daily for two months)15 17
• Etidronate (5 mg/kg daily for six months, or 10mg/kg daily
for three months)18
• Tiludronic acid (400 mg daily for three months).19
The first two come as intravenous preparations, whereas the
last three are oral preparations. They are associated with a
50-80% reduction in plasma concentrations of alkaline
phosphatase, and an improvement in bone pain and appearance
on radionuclide scanning.
Serum creatinine, calcium, and vitamin D concentrations should
bemeasured before using intravenous bisphosphonates, because
severe hypocalcaemia can occur with pre-existing vitamin D
deficiency. Consider reducing the dosage and infusion rate in
patients with mild renal impairment. Intravenous
bisphosphonates are generally well tolerated, although some
patients may experience febrile reactions, especially after the
first infusion. Febrile reactions are self limiting and easily
managed with paracetamol.
Oral bisphosphonates, on the other hand, are poorly absorbed
from the gastrointestinal tract and associated with
gastrointestinal side effects. It is recommended that oral
bisphosphonates are taken with a full glass of water on an empty
stomach and that patients wait for at least half an hour before
eating or drinking. Adequate intake of calcium (1000-1500 mg
daily) and vitamin D (800-1000 IU daily) is recommended
before and after treatment with bisphosphonates. Ocular side
effects including conjunctivitis and uveitis have been reported
with bisphosphonates, but these complications are rare.
Serum alkaline phosphatase concentrations usually fall within
7-10 days of starting bisphosphonates, but the nadir occurs three
to six months later. Pain relief and normalisation of serum
alkaline phosphatase are the goals of treatment. Serum alkaline
phosphatase should be monitored every three months for the
first six months of treatment, and at six monthly intervals months
thereafter. Retreatment with bisphosphonates may be considered
in patients with recurrence of bone pain or biochemical relapse,
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defined as an increase in alkaline phosphatase of 25% above
the nadir.13
Patient outcome
A radionuclide bone scan showed intense tracer uptake over L3
and the right radius, with a patchy increase in uptake over the
skull (fig 4). Radiography of the lumbar spine showed a
heterogeneous increase in density of the L3 vertebral body, with
bony expansion (fig 5). She was treated with a single infusion
of 60 mg pamidronate and had a mild febrile illness for a few
days after treatment. Her ALP fell from 277 U/L to 110 U/L in
three months.
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Fig 4 Radionuclide bone scan showing intense tracer
uptake over L3 and the right radius, with a patchy increase
in uptake over the skull
Fig 5 Radiography of the lumbar spine showing a
heterogeneous increase in density of the L3 vertebral body
and bony expansion
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